Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2018 Apr 26

PMID 29693354

Citations 6

Authors

Shatha Th Ahmed

Azad M Ahmed

Dildar H Musa

Farhad K Sulayvani

Muzahm Al-Khyatt

Intisar S Pity

Affiliations

Soon will be listed here.

Abstract

Background and objectives: To date, many tumor markers have been used to predict prognosis and therapeutic response in patients with breast cancer. The well established and routinely applied tumor markers are the estrogen-receptor, progesterone-receptor and Her2/neu-receptor. In the current study, we aimed to highlight any association of the proliferation index (Ki67) in breast infiltrative duct carcinoma with the tumor grade, tumor size and nodal status in addition to hormone receptor status. Tissue sections were stained immunohistochemically for Ki67 nuclear antigen, estrogen, progesterone and Her2/neu receptors using an automated Dako machine (Dako Denmark. There was a significant inverse relationship of Ki67 levels with ER and PR, while values were directly proportional to the tumor grade and Her2/neu status. No significant association was found between Ki67 and size of tumor or nodal status. Ki67 immunoexpression may offer an independent predictive tumor marker and for routine application in cases of breast cancer.

Citing Articles

The 1000 Mitoses Project: A Consensus-Based International Collaborative Study on Mitotic Figures Classification.

Lin S, Tran C, Bandari E, Romagnoli T, Li Y, Chu M Int J Surg Pathol. 2024; 32(8):1449-1458.

PMID: 38627896 PMC: 11497755. DOI: 10.1177/10668969241234321.

The Role of miRNAs in the Prognosis of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.

Santana T, de Oliveira Passamai L, de Miranda F, Borin T, Borges G, Luiz W Diagnostics (Basel). 2023; 13(1).

PMID: 36611419 PMC: 9818368. DOI: 10.3390/diagnostics13010127.

Arterial Spin Labeling Perfusion in Determining the IDH1 Status and Ki-67 Index in Brain Gliomas.

Batalov A, Zakharova N, Chekhonin I, Pogosbekyan E, Sudarikova A, Goryainov S Diagnostics (Basel). 2022; 12(6).

PMID: 35741254 PMC: 9221904. DOI: 10.3390/diagnostics12061444.

Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer.

Ankill J, Aure M, Bjorklund S, Langberg S, Kristensen V, Vitelli V NAR Cancer. 2022; 4(1):zcac008.

PMID: 35350772 PMC: 8947789. DOI: 10.1093/narcan/zcac008.

Fatty acid synthetase expression in triple-negative breast cancer.

Park J, Han H, Lim S, Kim W, Park K, Yoo Y J Pathol Transl Med. 2022; 56(2):73-80.

PMID: 35051326 PMC: 8935000. DOI: 10.4132/jptm.2021.10.27.

References

Shapochka D, Zaletok S, Gnidyuk M . Relationship between NF-κB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Exp Oncol. 2013; 34(4):358-63. View

Luporsi E, Andre F, Spyratos F, Martin P, Jacquemier J, Penault-Llorca F . Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2011; 132(3):895-915. PMC: 3332349. DOI: 10.1007/s10549-011-1837-z. View

Ruiz C, Seibt S, Al Kuraya K, Siraj A, Mirlacher M, Schraml P . Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer. 2005; 118(9):2190-4. DOI: 10.1002/ijc.21581. View

Shokouh T, Ezatollah A, Barand P . Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study. Medicine (Baltimore). 2015; 94(32):e1359. PMC: 4616694. DOI: 10.1097/MD.0000000000001359. View

Gonzalez-Sistal A, Baltasar Sanchez A, Del Rio M, Arias J, Herranz M, Ruibal A . Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program. Anticancer Res. 2014; 34(1):269-73. View

Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N . Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 2012; 1(5):747-754. PMC: 3445951. DOI: 10.3892/etm.2010.133. View

Yan J, Liu X, Han L, Xiao G, Li N, Deng Y . Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis. Asian Pac J Cancer Prev. 2015; 16(2):823-9. DOI: 10.7314/apjcp.2015.16.2.823. View

Inwald E, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M . Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013; 139(2):539-52. PMC: 3669503. DOI: 10.1007/s10549-013-2560-8. View

Elkablawy M, Albasri A, Mohammed R, Hussainy A, Nouh M, Alhujaily A . Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients. Saudi Med J. 2016; 37(2):137-41. PMC: 4800910. DOI: 10.15537/smj.2016.2.12285. View

10.

Li F, Wu S, Zhou J, Sun J, Lin Q, Lin H . Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. PLoS One. 2014; 9(2):e87264. PMC: 3911937. DOI: 10.1371/journal.pone.0087264. View

11.

Matsubara N, Mukai H, Itoh K, Nagai S . Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancer. Oncology. 2012; 81(5-6):345-52. DOI: 10.1159/000334920. View

12.

Scholzen T, Gerdes J . The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182(3):311-22. DOI: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9. View

13.

Esteva F, Hortobagyi G . Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004; 6(3):109-18. PMC: 400674. DOI: 10.1186/bcr777. View

14.

Madani S, Payandeh M, Sadeghi M, Motamed H, Sadeghi E . The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients. Indian J Med Paediatr Oncol. 2016; 37(2):95-9. PMC: 4854054. DOI: 10.4103/0971-5851.180136. View

15.

Tawfik K, Kimler B, Davis M, Fan F, Tawfik O . Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum Pathol. 2012; 44(1):39-46. DOI: 10.1016/j.humpath.2012.05.007. View

16.

Effi A, Aman N, Koui B, Koffi K, Traore Z, Kouyate M . Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast. BMC Cancer. 2017; 17(1):115. PMC: 5297122. DOI: 10.1186/s12885-017-3105-z. View

17.

Trihia H, Murray S, Price K, Gelber R, Golouh R, Goldhirsch A . Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?. Cancer. 2003; 97(5):1321-31. DOI: 10.1002/cncr.11188. View

18.

Joensuu K, Leidenius M, Kero M, Andersson L, Horwitz K, Heikkila P . ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. Breast Cancer (Auckl). 2013; 7:23-34. PMC: 3579427. DOI: 10.4137/BCBCR.S10701. View

19.

Haroon S, Hashmi A, Khurshid A, Kanpurwala M, Mujtuba S, Malik B . Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev. 2013; 14(7):4353-8. DOI: 10.7314/apjcp.2013.14.7.4353. View

20.

Cheang M, Chia S, Voduc D, Gao D, Leung S, Snider J . Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101(10):736-50. PMC: 2684553. DOI: 10.1093/jnci/djp082. View